Drug-target residence time and its implications for lead optimization
The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Much of drug discovery today is predicated on the concept of selective targeting of particular bioactive macromolecules by low-molecular-mass drugs. The binding of drugs to their macromolecular targets is therefore seen as paramount for pharmacological activity. In vitro assessment of drug-target interactions is classically quantified in terms of binding parameters such as IC(50) or K(d). This article presents an alternative perspective on drug optimization in terms of drug-target binary complex residence time, as quantified by the dissociative half-life of the drug-target binary complex. We describe the potential advantages of long residence time in terms of duration of pharmacological effect and target selectivity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The translation between slow inhibitor binding kinetics and sustained pharmacodynamic modulation has been studied for a numberoftarget classes (58).”
From Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability (2013) · cites this paper as [58]
In the citing paper
“Furthermore, the targets of infectious diseases usually have high replication rates, while covalent inhibitors tend to have long residence times making them less effective in this area [128].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [128]
In the citing paper
“Furthermore, longer residence times of drugs with their targets, as a result of slower off-rates, is a useful mechanism to extend in-vivo efficacy (59–61).”
From A PKA-selective inhibitor captures an open but more ordered conformation of the PKA catalytic subunit (2026) · cites this paper as [59]
Citations
Cites
Catalysis in chemistry and enzymology
Jencks, W. P. (1969) · Medical Entomology and Zoology · Cited by 3,217
Structure and Mechanism in Protein Science
Fersht, A. (1998) · Cited by 1,882
A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib)
Wood, E. R., Truesdale, A. T., McDonald, O. B., Yuan, D., Hassell, A., Dickerson, S. H., Ellis, B., Pennisi, C., Horne, E., Lackey, K., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1168 · Cited by 1,122
Copeland, R. A. (2005) · PubMed · Cited by 1,092
Self-citationLiang, J., Woodward, C., & Edelsbrunner, H. (1998) · Protein Science · doi:10.1002/pro.5560070905 · Cited by 1,057
Enzymes: a practical introduction to structure, mechanism, and data analysis
(2001) · Choice Reviews Online · doi:10.5860/choice.38-3881 · Cited by 1,056
Optical biosensors in drug discovery
Cooper, M. A. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd838 · Cited by 1,015
Oppenheimer, N. J., & James, T. L. (1989) · Academic Press eBooks · Cited by 820
Rusnak, D. W., Lackey, K. E., Affleck, K., Wood, E. R., Alligood, K. J., Rhodes, N., Keith, B. R., Murray, D. M., Knight, W. B., Mullin, R. J., et al. (2001) · PubMed · Cited by 728
Enzymes: A Practical Introduction to Structure, Mechanism, and Data Analysis
Copeland, R. A. (2000) · Wiley eBooks · doi:10.1002/0471220639 · Cited by 726
Self-citationSteroid-hormone rapid actions, membrane receptors and a conformational ensemble model
Norman, A. W., Mizwicki, M. T., & Norman, D. P. G. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1283 · Cited by 569
The kinetics of competitive radioligand binding predicted by the law of mass action.
Motulsky, H. J., & Mahan, L. C. (1984) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)15016-5 · Cited by 414
Chan, C.-C., Boyce, S., Brideau, C., Charleson, S., Cromlish, W., Ethier, D., Evans, J., Ford-Hutchinson, A. W., Forrest, M. J., Gauthier, J. Y., et al. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)34934-1 · Cited by 398
Biochemical mechanisms of drug action: what does it take for success?
Swinney, D. C. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1500 · Cited by 394
Maschera, B., Darby, G., Palú, G., Wright, L. L., Tisdale, M., Myers, R., Blair, E. D., & Furfine, E. S. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.52.33231 · Cited by 381
Characteristic Physical Properties and Structural Fragments of Marketed Oral Drugs
Vieth, M., Siegel, M. G., Higgs, R. E., Watson, I. A., Robertson, D. H., Savin, K. A., Durst, G. L., & Hipskind, P. A. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm030267j · Cited by 359
Kapur, S., & Seeman, P. M. (2000) · PubMed · Cited by 284
Efficacy at g-protein-coupled receptors
Kenakin, T. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd722 · Cited by 263
Methotrexate, a high-affinity pseudosubstrate of dihydrofolate reductase
Williams, J. W., Morrison, J. F., & Duggleby, R. G. (1979) · Biochemistry · doi:10.1021/bi00579a021 · Cited by 227
A Pharmacology Primer: Theory, Applications, and Methods
Kenakin, T. (2006) · Cited by 173
Lacourcière, Y. (1999) · American Journal of Hypertension · doi:10.1016/s0895-7061(99)00142-9 · Cited by 169
Bull, H. G., Garcia-Calvo, M. M., Andersson, S., Baginsky, W. F., Chan, H. K., Ellsworth, D. E., Miller, R. R., Stearns, R. A., Bakshi, R. K., Rasmusson, G. H., et al. (1996) · Journal of the American Chemical Society · doi:10.1021/ja953069t · Cited by 161
Candesartan (CV-11974) dissociates slowly from the angiotensin AT1 receptor
Ojima, M., Inada, Y., Shibouta, Y., Wada, T., Sanada, T., Kubo, K., & Nishikawa, K. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(96)00837-0 · Cited by 143
Copeland, R. A. (1994) · Springer eBooks · doi:10.1007/978-1-4757-1505-7 · Cited by 134
Self-citationLewandowicz, A., Tyler, P. C., Evans, G. B., Furneaux, R. H., & Schramm, V. L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.c300259200 · Cited by 126
Gooljarsingh, L. T., Fernandes, C., Yan, K., Zhang, H., Grooms, M. H., Johanson, K., Sinnamon, R. H., Kirkpatrick, R. B., Kerrigan, J. J., Lewis, T. S., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0602650103 · Cited by 118
Self-citationBerezov, A., Zhang, H., Greene, M. I., & Murali, R. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm000527m · Cited by 108
Kati, W. M., Montgomery, D., Carrick, R. J., Gubareva, L. V., Maring, C. J., McDaniel, K. F., Steffy, K. R., Molla, A., Hayden, F. G., Kempf, D. J., et al. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.4.1014-1021.2002 · Cited by 103
Kinetic Exclusion Assay Technology: Characterization of Molecular Interactions
Darling, R. J., & Brault, P.-A. (2004) · Assay and Drug Development Technologies · doi:10.1089/adt.2004.2.647 · Cited by 92
Maschera, B., Furfine, E. S., & Blair, E. D. (1995) · Journal of Virology · doi:10.1128/jvi.69.9.5431-5436.1995 · Cited by 74
Address in Pathology ON CHEMOTHERAPEUTICS:
(1913) · The Lancet · doi:10.1016/s0140-6736(01)38705-6 · Cited by 62
Billheimer, J. T., Dicker, I. B., Wynn, R., Bradley, J. D., Cromley, D. A., Godonis, H. E., Grimminger, L. C., He, B., Kieras, C. J., Pedicord, D. L., et al. (2002) · Blood · doi:10.1182/blood.v99.10.3540 · Cited by 60
Angiotensin II type 1 receptor antagonists
Vanderheyden, P., Fierens, F. L. P., & Vauquelin, G. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00388-9 · Cited by 54
Shuman, C. F., Markgren, P.-O., Hämäläinen, M., & Danielson, U. H. (2003) · Antiviral Research · doi:10.1016/s0166-3542(03)00002-0 · Cited by 52
Methods for protein analysis : a practical guide to laboratory protocols
Copeland, R. A. (1994) · Medical Entomology and Zoology · Cited by 50
Self-citationMousa, S. A., Bozarth, J. M., Naik, U. P., & Slee, A. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703943 · Cited by 50
Steroid 5α-reductase inhibitors in androgen-dependent disorders
Harris, G. S., & Kozarich, J. W. (1997) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(97)80017-8 · Cited by 44
Shuman, C. F., Vrang, L., & Danielson, U. H. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm0499110 · Cited by 42
A Novel N-Methyl-d-aspartate Receptor Open Channel Blocker with in Vivo Neuroprotectant Activity
Planells‐Cases, R., Montoliu, C., Humet, M., Fernández-Carvajal, A. M., Garcı́a-Martı́nez, C., Valera, E., Merino, J. M., Pérez‐Payá, E., Messeguer, Á., Felipo, V., et al. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.302.1.163 · Cited by 38
Seiffert, D., Stern, A. M., Ebling, W. F., Rossi, R. J., Barrett, Y. C., Wynn, R., Hollis, G. F., He, B., Kieras, C. J., Pedicord, D. L., et al. (2002) · Blood · doi:10.1182/blood-2002-02-0471 · Cited by 34
In Vivo Time-Dependent Inhibition of Human Steroid 5a-Reductase by Finasteride
Tian, G. (1996) · Journal of Pharmaceutical Sciences · doi:10.1021/js950100g · Cited by 30
Inada, Y., Ojima, M., Kanagawa, R., Misumi, Y., Nishikawa, K., & Naka, T. (1999) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1000749 · Cited by 23
Action of Atypical Antipsychotics
Meltzer, H. Y. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.1.153-a · Cited by 21
Paradigm shift in NMDA receptor drug development
Lipton, S. A., & Chen, H.-S. V. (2005) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.9.3.427 · Cited by 14
Abrahamsson, T. (1998) · American Journal of Hypertension · doi:10.1016/s0895-7061(97)90832-3 · Cited by 10
Action of Atypical Antipsychotics
Shim, S. S. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.1.154 · Cited by 5
Cited by
The resurgence of covalent drugs
Singh, J., Petter, R. C., Baillie, T. A., & Whitty, A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3410 · Cited by 1,873
How were new medicines discovered?
Swinney, D. C., & Anthony, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3480 · Cited by 1,812
The cellular thermal shift assay for evaluating drug target interactions in cells
Jafari, R., Almqvist, H., Axelsson, H., Ignatushchenko, M., Lundbäck, T., Nordlund, P., & Molina, D. M. (2014) · Nature Protocols · doi:10.1038/nprot.2014.138 · Cited by 1,474
Role of Molecular Dynamics and Related Methods in Drug Discovery
De Vivo, M., Masetti, M., Bottegoni, G., & Cavalli, A. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01684 · Cited by 1,297
Roskoski, R. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2015.10.021 · Cited by 886
Metadata
- Authors
- Copeland, R. A., Pompliano, D. L., & Meek, T. D.
- Affiliations
- GlaxoSmithKline (United States) (US)
- Corresponding author
- Copeland, Robert A.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2006-08-04
- Volume
- 5
- Issue
- 9
- Pages
- 730-739
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2016408686
- Semantic Scholar
- 362824beb2008831aa65b4eb774e5c8703ff9c71
- Cited by
- 1,464
- References
- 46
- Citations by year
- 2026: 83 · 2025: 64 · 2024: 78 · 2023: 79 · 2022: 81 · 2021: 76 · 2020: 83 · 2019: 88 · 2018: 102 · 2017: 104 · 2016: 96 · 2015: 120 · 2014: 74 · 2013: 88 · 2012: 65
- FWCI
- 2.81
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Interaction Studies and Fluorescence Analysis
- Keywords
- drug-target residence time, lead optimization, drug selectivity, drug-target binding, binding affinity
- MeSH terms
- Binding, Competitive, Pharmaceutical Preparations, Humans, Kinetics, Ligands, Technology, Pharmaceutical, Drug Design, Drug Delivery Systems, Macromolecular Substances
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.